WuXi Biologics (Cayman) Inc. has announced the expansion of its global capabilities with the launch of a modular Drug Product (DP) facility at its Singapore CRDMO hub. This innovative facility, designed in collaboration with Pharmadule Morimatsu, aims to accelerate construction and manufacturing timelines, allowing for rapid adaptation to diverse product formats. The finished facility will be one of the world's largest modular biologics DP facilities, strengthening WuXi Biologics' leadership in end-to-end DP capabilities. Additionally, a Drug Substance (DS) modular facility is in the planning stages for the Singapore hub. This expansion highlights WuXi Biologics' commitment to enhancing its global network to support clients' innovative pursuits and improve the accessibility and affordability of high-quality biologics worldwide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.